Chinook Therapeutics, Inc.
106 articles about Chinook Therapeutics, Inc.
-
Chinook Therapeutics Announces Upcoming Presentations and Investor Conference Call at the 60th European Renal Association (ERA) Congress
5/5/2023
Chinook Therapeutics, Inc. today announced upcoming data presentations at the 60th ERA Congress from June 15 – 18, 2023, both virtual and live in Milan, Italy.
-
Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - May 5, 2023
5/5/2023
Chinook Therapeutics, Inc. today announced that the Compensation Committee of the Company’s Board of Directors approved new employment inducement grants of stock options to purchase a total of 88,000 shares of common stock and restricted stock units for 44,600 shares with a grant date of April 28, 2023.
-
Chinook Therapeutics to Present at Upcoming May 2023 Investor Conferences
4/27/2023
Chinook Therapeutics, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, announced that Chinook management is scheduled to participate in the following upcoming investor conferences.
-
Chinook Therapeutics Announces the Appointment of Robert W. Azelby to its Board of Directors
4/13/2023
Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced the appointment of Robert W. Azelby to its Board of Directors.
-
Chinook Therapeutics to Present at Upcoming April 2023 Investor Conferences
4/11/2023
Chinook Therapeutics, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, announced that Chinook management is scheduled to participate in the following upcoming investor conferences.
-
Chinook Therapeutics Announces Voluntary Pause in Dosing of CHK-336 in Ongoing Phase 1 Clinical Trial in Healthy Volunteers
4/11/2023
Chinook Therapeutics, Inc. today announced that dosing in the phase 1 clinical trial of CHK-336 in healthy volunteers has been voluntarily paused to allow a thorough investigation of a serious adverse event (SAE) that occurred in a single subject following the first dose in the 125 mg multiple ascending dose (MAD) group.
-
Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - April 7, 2023
4/7/2023
Chinook Therapeutics, Inc. today announced that the Compensation Committee of the Company’s Board of Directors approved new employment inducement grants of stock options to purchase a total of 85,500 shares of common stock and restricted stock units for 44,580 shares with a grant date of March 31, 2023.
-
Chinook Therapeutics to Present at the Guggenheim Healthcare Talks | Genomic Medicines and Rare Disease Days
3/28/2023
Chinook Therapeutics, Inc. announced that Chinook management is scheduled to participate in a virtual fireside chat at the Guggenheim Healthcare Talks | Genomic Medicines and Rare Disease Days on Tuesday, April 4th at 10:45 am ET, as well as 1x1 meetings with investors.
-
Chinook Therapeutics Announces Upcoming Presentations at ISN World Congress of Nephrology 2023
3/23/2023
Chinook Therapeutics, Inc. today announced presentations at the ISN World Congress of Nephrology 2023 from March 30 – April 2, 2023 in Bangkok, Thailand.
-
Chinook Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference
3/7/2023
Chinook Therapeutics, Inc. today announced that Chinook management is scheduled to participate in a virtual fireside chat at the Oppenheimer 33rd Annual Healthcare Conference on Tuesday, March 14, 2023 at 3:20 pm ET, as well as 1x1 meetings.
-
Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - March 03, 2023
3/3/2023
Chinook Therapeutics, Inc. announced that the Compensation Committee of the Company’s Board of Directors approved new employment inducement grants of stock options to purchase a total of 202,290 shares of common stock and restricted stock units for 61,145 shares with a grant date of January 31, 2023 for nine new employees.
-
Chinook Therapeutics Announces Upcoming Presentations at the 5th Chronic Kidney Disease Drug Development Summit
2/28/2023
Chinook Therapeutics, Inc. today announced upcoming presentations at the 5th Chronic Kidney Disease Drug Development (CKD) Summit in Boston, MA from March 7 – 9, 2023.
-
Chinook Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates
2/27/2023
Chinook Therapeutics, Inc. reported financial results for the fourth quarter and year ended December 31, 2022 and provided corporate updates.
-
Chinook Therapeutics Announces the Appointment of Andrew Oxtoby as Chief Commercial Officer
2/15/2023
Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced the appointment of Andrew Oxtoby as chief commercial officer.
-
Chinook Therapeutics to Present at SVB Securities Global Biopharma Conference
2/7/2023
Chinook Therapeutics, Inc. (Nasdaq: KDNY) today announced that Chinook management is scheduled to participate in a virtual fireside chat at the SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023 at 11:20 am ET, as well as 1x1 meetings.
-
Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - February 06, 2023
2/6/2023
Chinook Therapeutics, Inc. announced that the Compensation Committee of the Company’s Board of Directors approved new employment inducement grants of stock options to purchase a total of 28,957 shares of common stock and restricted stock units for 14,478 shares with a grant date of January 31, 2023 for five new employees pursuant to the Company’s 2022 Equity Inducement Plan.
-
Chinook Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
1/3/2023
Chinook Therapeutics, Inc. announced that Chinook management will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 11, 2023 at 11:15 am EST, and participate in 1x1 meetings.
-
Chinook Therapeutics to Present at Upcoming Investor Conferences - November 22, 2022
11/22/2022
Chinook Therapeutics, Inc. announced that Chinook management is scheduled to participate in fireside chats and one-on-one meetings at the following upcoming investor conferences:
-
Therapeutics to halt the progression of chronic kidney disease are in Phase III trials, and others will enter that stage soon. NDAs could follow as early as 2024 with regulatory determinations in 2025. -
Chinook Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results
11/10/2022
Chinook Therapeutics, Inc. provided a business update and reported financial results for the quarter and nine months ended September 30, 2022.